cardiology careers collections past issues search home
     

J Am Coll Cardiol, 2007; 49:2073-2080, doi:10.1016/j.jacc.2007.01.089 (Published online 11 May 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doyle, B.
Right arrow Articles by Caplice, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Doyle, B.
Right arrow Articles by Caplice, N.

Plaque Neovascularization and Antiangiogenic Therapy for Atherosclerosis

Brendan Doyle, MD* and Noel Caplice, MD, PhD{dagger},*

* Division of Cardiovascular Diseases, Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota
{dagger} Centre for Research in Vascular Biology, Biosciences Institute, University College Cork, Cork, Ireland


Figure 1
View larger version (71K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Mechanisms of Vessel Wall Neovascularization in Atherosclerosis

Increased proangiogenic activity, which may be accompanied by reduced endogenous inhibition of angiogenesis, results in vasa vasorum proliferation and intimal neovascularization. FGF = fibroblast growth factors; HGF = hepatocyte growth factor; PDGF = platelet-derived growth factor; SMC = smooth muscle cell; VEGF= vascular endothelial growth factor. Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.

 

Figure 2
View larger version (97K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Role of Vessel Wall Neovascularization in Plaque Growth

Possible roles for microvessels in disease progression include the supply of cellular and soluble lesion components, enhancement of intraplaque gas exchange, and delivery of metabolic substrates to the plaque core. ICAM = intercellular adhesion molecule; LDL = low-density lipoprotein; VCAM = vascular cell adhesion molecule. Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.

 

Figure 3
View larger version (72K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3 Intraplaque Hemorrhage

Plaque neovessels are of relatively large caliber and poorly invested with smooth muscle cells, a structural weakness that may be further compromised by matrix degrading enzymes released by inflammatory cells. Intraplaque hemorrhage from these vessels may contribute to plaque instability and/or lesion expansion. MMPs = matrix metalloproteinases. Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.

 




 
  cardiology careers collections past issues search home